Racetams (piracetam, aniracetam, phenylpiracetam)

Racetams are a family of synthetic compounds built around a pyrrolidone ring, the most common being piracetam, aniracetam, and phenylpiracetam. They were the original nootropics. Piracetam was synthesised in the 1960s and the others were variations on the same scaffold designed to be more potent or hit different mechanisms. People take them for cognitive support: clearer thinking under load, better verbal recall, less mental fatigue on long workdays. They're not stimulants in the caffeine or amphetamine sense, the effect is subtler and tends to feel more like the brain just running smoother than a noticeable lift.

What they share: a pyrrolidone ring, mostly renal clearance, increased cholinergic activity in the brain (which is why a choline pairing often helps), and a wide safety margin. Beyond that, the mechanisms diverge sharply, which is why the three aren't really interchangeable.

Quick rundown:

Piracetam — the gentle workhorse. Slow, subtle, takes weeks to build. Best for chronic cognitive support, older adults, post-stroke recovery, and post-surgical cognitive decline. Young healthy users often feel nothing

Aniracetam — the faster, mood-leaning one. Fat-soluble, kicks in within an hour, often described as taking the edge off anxiety while sharpening verbal flow. Best for situational use during stressful or socially demanding situation.

Phenylpiracetam — the stimulant of the family. Acts like a low-dose modafinil, banned by WADA, and the only one most people will actually feel. Best for high-leverage moments (a long deadline, a hard exam, a brutal travel day). Tolerance builds fast, so pulse it

Less common racetams:

Oxiracetam — sits between piracetam and phenylpiracetam in potency. Stronger cognitive effect than piracetam, especially on logic and verbal fluency, without the stimulant edge. Decent trial base in dementia and post-concussive cognitive impairment. The natural fourth choice if piracetam feels too subtle

Pramiracetam — the choline-uptake one. Fat-soluble, very potent by weight, works through a unique mechanism of increasing high-affinity choline uptake into hippocampal neurons. Studied in traumatic brain injury and age-related memory loss. Smaller evidence base but a real distinct mechanism

Coluracetam — also acts on high-affinity choline uptake. Anecdotal reports around visual perception and mood, but the clinical evidence is essentially zero (one unpublished failed phase 2 in major depression). Not enough data to recommend with confidence

Nefiracetam — binds nicotinic acetylcholine receptors and has been studied for post-stroke apathy and depression. Trial base is thin and human availability is limited. Skippable unless completeness matters

Fasoracetam — GABA-B receptor focused, was being investigated for ADHD in adolescents with mGluR mutations before the trial programme stalled. Largely a research curiosity, not enough clinical data to act on

Levetiracetam — technically a racetam, but a prescription anticonvulsant for epilepsy with a totally different mechanism (SV2A binding) and a real side-effect profile including mood disturbance and aggression. Don't treat it as interchangeable with the cognitive racetams

Deep-dive

Piracetam is the parent molecule, 2-oxo-1-pyrrolidine acetamide, a cyclic GABA derivative that doesn't actually bind GABA receptors in any meaningful way. Its mechanism is unusual. The most established action is on neuronal membranes: piracetam binds to phospholipid head groups in the membrane bilayer and restores fluidity in aged or damaged membranes without affecting young, healthy ones. This translates downstream to better signal transduction, restored receptor density, and improved mitochondrial membrane potential and ATP synthesis. It's why piracetam tends to do more in older brains, dementia, or post-injury states than in young healthy users. It also has haemorheological effects, improving red blood cell deformability and reducing platelet hyperactivity, which is part of why it shows up in stroke and vascular cognitive decline trials.

The clinical evidence in cognitive impairment is real but specific. A meta-analysis of 19 double-blind placebo-controlled trials in elderly patients with cognitive impairment or dementia found a significant benefit on global clinical impression. In post-stroke aphasia, a 6-week trial with PET imaging showed piracetam improved language recovery and increased activated cerebral blood flow during word-repetition tasks. In coronary artery bypass surgery, a randomised trial found 12g/day starting before surgery significantly reduced the postoperative cognitive decline that's common after cardiopulmonary bypass. A meta-analysis on memory enhancement specifically was more equivocal, with high heterogeneity and no clean overall effect, so the picture isn't uniformly positive. Piracetam shines when there's an underlying deficit to correct, and gets less impressive in healthy young brains.

There's also a body of evidence in dyslexic children, mostly from the 1980s. A 36-week multicentre trial in 225 children at 3300 mg/day showed improvements in reading speed and verbal memory. A 12-week study in 257 dyslexic boys replicated the reading-speed finding. The effect is modest but consistent.

Aniracetam (1-(4-methoxybenzoyl)-2-pyrrolidinone) is fat-soluble, which means it absorbs faster, crosses the blood-brain barrier more readily, and has a much shorter half-life (1-3 hours vs piracetam's 5-6 hours). Its main mechanism is positive allosteric modulation of AMPA receptors. Detailed electrophysiology work shows aniracetam slows AMPA receptor deactivation and desensitisation, meaning glutamate signals at excitatory synapses last longer and more current flows per release event. This is the same mechanism that the ampakine drug class was built on, and it's the cleanest pharmacological story among the racetams. Through this AMPA potentiation, aniracetam enhances long-term potentiation in the hippocampus, which is the cellular substrate of learning and memory.

Aniracetam also has downstream effects on cholinergic, dopaminergic, and serotonergic systems via its metabolites (notably N-anisoyl-GABA and 2-pyrrolidinone). The clinical data in dementia is decent. A prospective study in 276 patients with cognitive disorders found aniracetam monotherapy maintained cognitive scores at 6 and 12 months and significantly improved emotional state at 3 months. The anxiolytic and mood-supporting effects show up consistently in animal models but human anxiety trials are sparse, so the subjective "takes the edge off" reports outpace the clinical evidence.

Phenylpiracetam (carphedon, phenotropil, fonturacetam) is piracetam with a phenyl group bolted onto the pyrrolidone ring. That single change makes it roughly 30-60x more potent by weight and gives it a fundamentally different pharmacology. The (R)-enantiomer is an atypical dopamine reuptake inhibitor acting at the dopamine transporter, similar in principle to modafinil. It also raises noradrenaline and increases the density of acetylcholine, NMDA, GABA, and dopamine receptors with chronic use. This is why it acts as a stimulant where the others don't, and why it's the only racetam explicitly banned by WADA for in-competition use.

Phenylpiracetam was developed in Russia and is prescribed there for asthenia, post-stroke recovery, ADHD-like symptoms, and chronic cerebral ischaemia. The clinical literature is overwhelmingly Russian-language and mostly open-label, which is a significant limitation when judging the evidence. Reported applications include cognitive recovery after ischaemic stroke and reduction of fatigue in cerebral ischaemia and asthenic syndromes. There's also a phase 1 trial of the (R)-enantiomer (MRZ-9547) for Parkinson's-related fatigue by Merz Pharma, which didn't progress further. Tolerance builds quickly, within days to weeks of daily use, which is the main practical limit.

Limits of the evidence. Most piracetam trials are in older populations with cognitive deficits, not healthy users seeking enhancement. The memory meta-analysis from 2024 couldn't confirm a clean memory-boosting effect even in cognitively impaired adults, with high between-trial heterogeneity. In acute ischaemic stroke given within 12 hours, piracetam didn't improve outcomes overall, with benefit only in post-hoc subgroups. Aniracetam's positive trials are mostly small, open-label, or in dementia populations, not healthy adults. Phenylpiracetam's stimulant and cognitive benefits in healthy users rest largely on user reports and Russian-language clinical practice rather than rigorous Western RCTs. None of the racetams are FDA-approved. Piracetam was reviewed by the EMA in the early 2000s and use was restricted in several EU countries. Treat the cognitive enhancement claims as plausible but not airtight.

Choline interaction. All three racetams increase cholinergic activity in the brain, which is part of how they work. The most common reported side effect, especially with piracetam and aniracetam, is a dull headache that many users report resolves with co-administered choline (alpha-GPC or CDP-choline at 300-600 mg). The mechanism isn't formally proven in controlled trials, but it's plausible: more demand on acetylcholine synthesis without enough substrate. A minority of people get the opposite, headaches from added choline, which usually means they were already sufficient.

Women. Almost all racetam trials enrolled both sexes but few report sex-stratified outcomes. The dyslexia trials were done largely in boys. The dementia and post-stroke trials included women throughout (often the majority, given the older demographic), with no signal that the cognitive effects differ. There are no sex-specific dose recommendations in the literature. Women on average have slightly slower renal clearance, which could mean modestly higher steady-state piracetam levels for the same mg dose since piracetam is excreted unchanged in urine. In practice this is rarely meaningful at standard doses, but if you're a small-framed woman dosing by typical "3g three times a day" you may sit at higher plasma levels than a 90 kg man on the same protocol. Pregnancy and breastfeeding are not studied for any of the three. Skip them in those windows.

Older adults. Piracetam's effects are most pronounced in aged brains, where membrane fluidity and mitochondrial function are already compromised. This is the population where it has the strongest clinical case. Doses tend to be on the higher end (4.8-9.6 g/day in dementia trials) and benefit takes weeks to emerge. Renal function declines with age, so dose reduction is appropriate if creatinine clearance is impaired, since all three are renally cleared with no significant hepatic metabolism for piracetam.

Dosage:

Piracetam: 1.6-4.8 g/day for cognitive support in healthy users, split into 2-3 doses. Dementia and post-stroke protocols go higher (4.8-9.6 g/day). Effect builds over weeks, not hours, so don't expect day-one results. An attack dose of 4.8 g three times daily for the first 2 days is common in clinical use to reach steady state faster. Older adults benefit at the higher end. Reduce dose if renal function is impaired

Aniracetam: 750-1500 mg per dose, 1-3 times daily. Take with food (it's fat-soluble, absorption is much better with dietary fat). Acts faster than piracetam, often noticeable within 30-60 minutes. Half-life is short so split dosing matters more here. Most users find 1500 mg twice daily a sensible ceiling

Phenylpiracetam: 100-200 mg, taken acutely before a demanding task, no more than 2-3 times per week. Daily use leads to tolerance within 1-2 weeks, after which the effect drops off sharply. This is the racetam that should be used situationally, not chronically. Avoid late-day dosing, the stimulant effect can disrupt sleep for 6+ hours

Choline pairing: If you get the characteristic dull racetam headache, add 300-600 mg alpha-GPC or CDP-choline alongside. Some users feel better cognitive effects with choline regardless. A minority feel worse, in which case drop the choline

Stacking: Aniracetam and piracetam stack reasonably well, hitting different mechanisms (AMPA modulation vs membrane fluidity). Phenylpiracetam doesn't need to be stacked with the others, it's potent enough on its own. Avoid combining phenylpiracetam with other stimulants (high-dose caffeine, ADHD medications, modafinil) without easing in, the cardiovascular load adds up

Cycling: Piracetam can be taken continuously without major tolerance. Aniracetam likewise, though some users notice diminishing subjective effect after months. Phenylpiracetam should be cycled aggressively, ideally pulsed use only, never daily for more than 2-3 weeks

Women: No specific dose adjustment, but smaller-framed users (under 60 kg) can start at the lower end of each range. Skip during pregnancy and breastfeeding

Older adults: Start lower and titrate up over 2-3 weeks. Check renal function before chronic high-dose piracetam

Here's what you can expect:

Piracetam. Subtle and slow. Most people notice nothing in the first week or two. By week 3-4 at 4.8 g/day, the typical report is verbal fluency that comes a bit easier, less of the mid-afternoon mental fog, and slightly steadier focus on long tasks. It doesn't feel like a stimulant. If you're young and healthy with no cognitive deficit, you may genuinely feel nothing and conclude it doesn't work. That's a reasonable conclusion for that demographic. The benefit is most apparent in people with a baseline deficit (age, post-injury, sleep-deprived weeks).

Aniracetam. Faster and more noticeable than piracetam. Within an hour of dosing on an empty stomach (or with fat), most users report a mild lift in mood, easier conversation, and a sense that thoughts come together more cleanly. Some describe a mild anxiolytic feel, less mental friction in social settings. Others feel nothing distinctive. The effect tapers within 3-4 hours, which is why split dosing matters.

Phenylpiracetam. This one you'll feel. Within 30-60 minutes of a 100-200 mg dose, expect a clear stimulant effect: focused, alert, mildly euphoric, willing to push through tedious work. It feels closer to a low-dose amphetamine or modafinil than to the other racetams. The downside is tolerance builds fast, the effect is mostly gone within 2-3 weeks of daily use, and overuse can leave you flat for days afterwards. Treat it like a tool for high-leverage moments, not a daily routine.

In the wrong context (well-rested, no cognitive load, expecting a feel-good experience), all three can underwhelm. They're tools for specific situations, not general mood enhancers.

Side effects & risks:

Headache is the most commonly reported side effect across all three, often described as a dull frontal pressure. Usually responds to added choline (alpha-GPC or CDP-choline 300-600 mg), or to lowering the dose. Some users get headaches from the choline itself, which usually means they don't need it

Insomnia if dosed late in the day, especially with phenylpiracetam (effect lasts 6+ hours) and aniracetam. Piracetam is less commonly disruptive to sleep but still best taken before mid-afternoon

Anxiety, irritability, or agitation can occur, more common with phenylpiracetam due to its stimulant action and with aniracetam in some users despite its anxiolytic reputation. Drop the dose or stop

GI discomfort, nausea, loose stools, especially at higher piracetam doses (above 4.8 g/day). Splitting the dose and taking with food helps

Tolerance and rebound are the practical limits with phenylpiracetam. Daily use blunts the effect within 1-2 weeks, and stopping after extended use can leave you mentally flat for several days. Pulse it

Cardiovascular load with phenylpiracetam, mild blood pressure and heart rate elevation. Avoid stacking with other stimulants without caution. Existing hypertension is a relative contraindication

Bleeding risk with piracetam at high doses. It improves red cell deformability and reduces platelet aggregation, which is part of why it's used in vascular indications, but means caution if you're on blood thinners (warfarin, DOACs, antiplatelets like clopidogrel) or have a bleeding disorder. Stop a week before any planned surgery

Renal clearance. Piracetam and phenylpiracetam are excreted mostly unchanged in urine. Reduced renal function means accumulation. Dose-reduce or avoid if creatinine clearance is impaired

Drug interactions. Phenylpiracetam stacks badly with monoamine-affecting drugs (MAOIs, high-dose stimulants, some SSRIs). Piracetam can mildly potentiate thyroid hormone effects in patients on T4. Aniracetam has minimal documented interactions but caution with other AMPA modulators or NMDA-affecting drugs

WADA status. Phenylpiracetam is on the WADA prohibited list (in-competition). Tested athletes should avoid it. Piracetam and aniracetam are not banned

Pregnancy and breastfeeding. No safety data for any of the three. Skip them

Long-term safety. Piracetam has the longest track record, with decades of European clinical use at gram doses without major safety signals. Aniracetam and phenylpiracetam have far less long-term human data, especially outside Eastern Europe and Russia. Treat extended daily use as understudied

🩸

Blood markers

Renal function (creatinine, eGFR), baseline before chronic piracetam or phenylpiracetam use, especially at higher doses or if you're over 50. Both are renally cleared. Recheck at 3-6 months if using regularly above 4.8 g/day piracetam.

Blood pressure and resting heart rate, baseline before phenylpiracetam, particularly if you're stacking with other stimulants. Re-measure during use to catch any drift.

Coagulation panel (platelets, PT/INR) if you're on anticoagulants or antiplatelets and considering chronic piracetam at gram doses. Piracetam reduces platelet aggregation, which adds to bleeding risk.

TSH, free T4, free T3, baseline if you're on thyroid medication and starting piracetam, since piracetam can mildly potentiate thyroid hormone action. Recheck at 6-8 weeks.

For most healthy users taking aniracetam acutely, or piracetam at standard cognitive-support doses without other risk factors, no specific bloodwork is needed.

Sold without prescription in some countries (the US treats them as unregulated research compounds), prescription-only in much of Europe, and prescription-only in Russia for phenylpiracetam.